Amneal Pharmaceuticals Inc Class A (NASDAQ:AMRX) shares climbed 2.5% in premarket trading Thursday after the U.S. Food and Drug Administration authorized the company’s romidepsin injection solution.
The approved product is a romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials. The FDA granted the product Competitive Generic Therapy (CGT) designation, a status that makes the medication eligible for 180 days of market exclusivity.
The ready-to-use solution is positioned as an alternative to the romidepsin lyophilized powder formulation that requires reconstitution prior to administration. Amneal said the romidepsin injection solution references the earlier romidepsin solution that was marketed by Teva and subsequently withdrawn from the market several years ago.
Commercial context for the drug is modest but meaningful. IQVIA data show U.S. annual sales for romidepsin lyophilized powder in single-dose vials were approximately $78 million for the 12 months ended April 2026.
Romidepsin injection solution belongs to the class of histone deacetylase inhibitors and is indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy.
The most commonly reported adverse reactions associated with romidepsin injection solution include nausea, fatigue, infections, vomiting, anorexia, electrocardiogram ST-T wave changes, dysgeusia, constipation and pruritus. Laboratory monitoring is relevant because Grade 3-4 laboratory abnormalities observed with the therapy include lymphopenia, neutropenia, anemia and thrombocytopenia.
Amneal noted that, since the FDA began tracking CGT approvals in 2018, the company has received more CGT approvals than any other firm in the industry.
Context and implications
The FDA approval provides Amneal with a ready-to-use branded generic alternative to a lyophilized powder formulation and the CGT designation offers a defined period of exclusivity that can affect short-term commercial positioning in the agent’s market.
Investors responded to the approval with a modest premarket uptick in the company’s stock price.